 |
市場調查報告書
商品編碼
1706029
全球莫基奧症候群（MPS-IV）藥物市場按產品類型、治療方法、疾病類型、分銷管道和地區分類Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type, By Treatment, By Disease Type, By Distribution Channel, By Geography |
||||||
2025 年全球 Morquio 症候群 (MPS-IV) 藥物市場規模估計為 190 萬美元，預計到 2032 年將達到 440 萬美元，2025 年至 2032 年的年複合成長率（CAGR）為 12.7%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 190萬美元 |
| 效能數據 | 從2020年到2024年 | 預測期 | 2025年至2032年 |
| 預測期：2025-2032年複合年成長率： | 12.70% | 2032年價值預測 | 440萬美元 |
黏多醣症IV 型 (MPS IV) 是一種罕見疾病，患者體內缺乏或沒有足夠的酵素來分解長鏈糖分子。這些分子鏈被稱為Glico（以前稱為粘多醣）。它是由分解硫酸角質素和硫酸軟骨素的酶 N-乙醯半乳糖胺-6-硫酸酯酶 (GALNS) 或 BETA-半乳糖苷酶缺乏引起的。當這些糖分在細胞、組織和器官中積聚時，會導致骨骼缺陷、身材矮小、關節異常、呼吸道阻塞等呼吸系統疾病、心臟病、聽力損失和角膜混濁。 MPS-IV 無法治療方法，治療方法僅限於症狀治療。然而，酵素替代療法（ERT）和造血幹細胞移植（HSCT）在控制症狀和改善患者生活品質方面已取得一些成功。 MPS IV 是一種遺傳性疾病。這意味著它通常在家庭內部傳承。如果父母雙方都攜帶無功能的 MPS IV 基因，則每個孩子患有 MPS IV 的幾率為 25%（四分之一）。這被稱為體染色體隱性遺傳。
市場動態：
全球莫基奧症候群 (MPS-IV) 藥物市場主要受到這種罕見遺傳病患疾病率上升、對可用治療方案的認知不斷提高以及具有新作用機制的藥物的強大管道的推動。然而，罕見疾病的高治療成本以及生產重組酶的挑戰正在抑制市場的成長。儘管如此，治療方法的改進、罕見疾病研發的增加以及提供市場獨佔權的孤兒藥資格的認定，為該市場的關鍵參與者提供了有利可圖的機會。
本研究的主要特點
- 本報告對全球莫爾基奧症候群 (MPS-IV) 藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期 (2025-2032) 的市場規模和年複合成長率(CAGR)。
- 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 主要公司簡介包括 BioMarin Pharmaceutical Inc.、工業有限公司、輝瑞公司、賽諾菲、諾和諾德 A/S、Concert Pharmaceuticals, Inc.、Alexion Pharmaceuticals Inc.、諾華公司、安進公司、Sangamo Therapeutics 和 JCR Pharmaceuticals Co.。
- 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
- 全球莫基奧症候群（MPS-IV）藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過用於分析全球莫爾基奧症候群（MPS-IV）藥物市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 加強宣傳宣傳活動
- 缺乏熟練的醫療保健專業人員
- 醫療成本上漲
- 主要亮點
- 監管情景
- 近期動態
- PEST分析
- 波特分析
- 產品發布
- 合併、收購和合作
4. 全球莫基奧症候群（MPS-IV）藥物市場-冠狀病毒（COVID-19）大流行的影響
- COVID-19流行病學
- 供需側分析
- 經濟影響
5. 2020 年至 2032 年全球莫基奧症候群（MPS-IV）藥物市場（依產品類型）
- 2025年和2032年市場佔有率分析（％）
- 與前一年同期比較成長分析
- 細分趨勢
- 固態劑型
- 市場規模及預測、與前一年同期比較
- 錠劑
- 膠囊
- 液體劑型
- 注射
- 其他
6. 全球莫基奧症候群（MPS-IV）藥物市場，依治療方法，2020 年至 2032 年
- 2025年和2032年市場佔有率分析（％）
- 與前一年同期比較成長分析
- 細分趨勢
- 酵素替代療法
- 造血幹細胞治療
- 基因治療
- 其他
7. 2020 年至 2032 年全球 Morquio 症候群（MPS-IV）藥物市場（依疾病類型）
- 2025年和2032年市場佔有率分析（％）
- 與前一年同期比較成長分析
- 細分趨勢
- 莫爾基奧
- 莫爾基奧
8. 全球莫基奧症候群（MPS-IV）藥物市場（依分銷管道分類），2020 年至 2032 年
- 2025年和2032年市場佔有率分析（％）
- 與前一年同期比較成長分析
- 細分趨勢
- 醫院藥房
- 網路藥局
- 零售藥局
9. 2020 年至 2032 年全球莫基奧症候群（MPS-IV）藥物市場（按地區）
- 2025年及2032年區域市場佔有率分析（％）
- 與前一年同期比較
- 國家趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第10章 競爭格局
- BioMarin Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited.
- Pfizer Inc.
- Sanofi
- Novo Nordisk A/S
- Concert Pharmaceuticals, Inc.
- Alexion Pharmaceuticals Inc.
- Novartis AG
- Amgen Inc.
- Sangamo Therapeutics
- JCR Pharmaceuticals Co., Ltd.
第 11 章 章節
- 參考
- 調查方法
- 關於出版商
Global Morquio Syndrome (MPS-IV) Drug Market is estimated to be valued at USD 1.9 Mn in 2025 and is expected to reach USD 4.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.70% | 2032 Value Projection: | USD 4.4 Mn |
Mucopolysaccharidosis type IV (MPS IV) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of sugar molecules. These chains of molecules are called glycosaminoglycans (formerly called mucopolysaccharides). It is caused by a deficiency in the enzymes N-acetylgalactosamine-6-sulfatase (GALNS) or beta-galactosidase which is responsible for breaking down keratan sulfate and chondroitin sulfate. The accumulation of these sugars in cells, tissues, and organs can lead to skeletal dysplasia, short stature, joint abnormalities, and respiratory issues like airway obstruction, heart defects, hearing loss, and corneal opacity. There is no cure for MPS-IV and the treatment options are limited to symptom management. However, enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) have shown some success in management of symptoms and improvement in quality of life for patients. MPS IV is an inherited disorder. This means, it is typically passed down through families. If both parents carry a nonworking copy of a gene that is related to this condition, each of their children has a 25% (1 in 4) chance of developing the disease. This is called an autosomal recessive trait.
Market Dynamics:
Global morquio syndrome (MPS-IV) drug market is primarily driven by the rising prevalence of this rare genetic disorder, growing awareness about available treatment options and strong pipeline drugs with novel mechanisms of action. However, high cost of therapy due to rarity of disease as well as challenges that are associated with production of recombinant enzymes are some of the factors restraining the market growth. Nonetheless, development of improved treatment modalities, increasing research funding for rare diseases and orphan drug designation providing market exclusivity offers lucrative opportunities for the key market players in this market.
Key features of the study:
- This report provides in-depth analysis of the global morquio syndrome (MPS-IV) drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global morquio syndrome (MPS-IV) drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include BioMarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited., Pfizer Inc., Sanofi, Novo Nordisk A/S, Concert Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc., Novartis AG, Amgen Inc., Sangamo Therapeutics, and JCR Pharmaceuticals Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global morquio syndrome (MPS-IV) drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global morquio syndrome (MPS-IV) drug market
Detailed Segmentation:
- Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type
- Solid Dosage Form
- Tablets
- Capsules
- Liquid Dosage Form
- Injectable
- Others
- Global Morquio Syndrome (MPS-IV) Drug Market, By Treatment
- Enzyme Replacement Therapy
- Hematopoietic Stem Cell Therapy
- Gene Therapy
- Others
- Global Morquio Syndrome (MPS-IV) Drug Market, By Disease Type
- Morquio A
- Morquio B
- Global Morquio Syndrome (MPS-IV) Drug Market, By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Global Morquio Syndrome (MPS-IV) Drug Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Company Profiles
- BioMarin Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited.
- Pfizer Inc.
- Sanofi
- Novo Nordisk A/S
- Concert Pharmaceuticals, Inc.
- Alexion Pharmaceuticals Inc.
- Novartis AG
- Amgen Inc.
- Sangamo Therapeutics
- JCR Pharmaceuticals Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Treatment
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Launch of Awareness Campaigns
- Lack of skilled healthcare professionals
- Rising healthcare expenditure
- Key Highlights
- Regulatory Scenario
- Recent Trends
- PEST Analysis
- PORTER's Analysis
- Product Launches
- Mergers, Acquisitions, and Collaborations
4. Global Morquio Syndrome (MPS-IV) Drug Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Solid Dosage Form
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Tablets
- Capsules
- Liquid Dosage Form
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Injectable
- Others
6. Global Morquio Syndrome (MPS-IV) Drug Market, By Treatment, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Hematopoietic Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
7. Global Morquio Syndrome (MPS-IV) Drug Market, By Disease Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Morquio A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Morquio B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
8. Global Morquio Syndrome (MPS-IV) Drug Market, By Distribution Channel, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
9. Global Morquio Syndrome (MPS-IV) Drug Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- BioMarin Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited.
- Pfizer Inc.
- Sanofi
- Novo Nordisk A/S
- Concert Pharmaceuticals, Inc.
- Alexion Pharmaceuticals Inc.
- Novartis AG
- Amgen Inc.
- Sangamo Therapeutics
- JCR Pharmaceuticals Co., Ltd.
- Analyst Views
11. Section
- References
- Research Methodology
- About us
